Du forlater nå GSKs nettsider

Denne lenken tar deg til en nettside som ikke tilhører GSK. GSK er ikke ansvarlig for, går ikke god for og aksepterer intet ansvar for informasjon eller meninger på nettsteder til tredjeparter

Fortsett

Tilbake

Tivicay tablet strengths

About TIVICAY

TIVICAY (dolutegravir) is a once-daily, unboosted integrase inhibitor for treatment of HIV infection in combination with other anti-retroviral medicines. 1

  • Tivicay 10 mg film-coated tablets
  • Tivicay 25 mg film-coated tablets
  • Tivicay 50 mg film-coated tablets

Learn more

This medicinal product is subject to additional monitoring.

References:

  1. TIVICAY preparatomtale
  2. European AIDS Clinical Society (EACS) Guidelines. Version 8.2 - January 2017. Available at: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html Last accessed 7th July 2017.
  3. Department of Health and Human Services (DHHS) Panel. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. July 14, 2016. Available at: http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0  Last accessed 7th July 2017.
  4. Günthard HF, Saag MS, Benson CA, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2016 Recommendations of the International Antiviral Society–USA Panel. JAMA. 2016;316(2):191-210. Available at: https://www.iasusa.org/content/antiretroviral-drugs-treatment-and-prevention-hiv-infection-adults-2016-recommendations Last accessed 7th July 2017.
  5. Faglige retningslinjer for oppfølging og behandling av hiv 2017, Norsk forening for Infeksjonsmedisin, januar 2017. http://legeforeningen.no/PageFiles/283348/Faglige-retningslinjer-hiv-2017.pdf (Accessed 08.09.2017).
  6. Llibre JM, Walmsley S, Gatell JM. Backbones versus core agents in initial ART regimens: one game, two players. J Antimicrob. Chemother. (2016); 71 (4): 856-861.

TIVICAY trademark is owned by or licensed to the ViiV Healthcare group of companies.